What is the difference between the mechanisms of action of Inavolisib and Carpisetin?

Inavolisib and Capmatinib are both targeted drugs used for cancer treatment, but their mechanisms of action are obviously different. They mainly target different molecular targets and are suitable for different tumor types.

Inaliset is a selective PI3Kα inhibitor that mainly acts on the α isoform in the PI3K (phosphatidylinositol 3kinase) signaling pathway. PI3KThe signaling pathway is extremely active in a variety of tumor cells, promoting tumor cell proliferation, survival and metabolism. Inaliset inhibits the growth and spread of tumor cells by inhibiting the activity of PI3Kα and blocking the signaling of this pathway. The drug is particularly suitable for patients with solid tumors such as breast cancer related to PIK3CA gene mutations.

In contrast, carpisetin is a highly selectiveMET tyrosine kinase inhibitor. MET is a receptor tyrosine kinase on the cell surface. When it is overexpressed or its gene is amplified, it activates downstream signaling pathways and promotes tumor invasion and metastasis. Carpisetin blocks the tyrosine kinase activity of the MET receptor and inhibits the transmission of abnormal signals, thereby slowing down the proliferation and spread of tumor cells. It is mainly used for patients with non-small cell lung cancer and other cancers with abnormal MET genes.

In addition, the different targets of the two also lead to differences in their indications and resistance mechanisms. Inalise focuses on the PI3K/AKT/mTOR signaling pathway and is suitable for patients with positive PIK3CA mutations, while carpisetin targets the abnormality of the MET pathway and is suitable for patients with MET amplification or mutation. Clinically, these two drugs can be individually selected based on the molecular characteristics of the tumor, helping to improve treatment effects and reduce side effects.

To sum up, although inaliside and carpisetin are both targeted therapeutic drugs, their mechanisms of action are completely different. Inaliset interferes with intracellular signaling by inhibiting PI3Kα, while carpisetin blocks signaling pathways by inhibiting the kinase activity of MET receptors. The molecular targets and indications targeted by the two are different, providing diversified options for precision tumor treatment.

Reference materials:https://www.drugs.com/